Key Studies Influencing My Practice Following EASL 2016 by David R. Nelson
Summary: A downloadable audio about the clinical impact of new data reported at the EASL’s International Liver Congress, held in Barcelona, in April. (47 minutes)
- Non–Genotype 1 HCV Now and in the Near Future by Jordan J. Feld, et al.
Summary: A downloadable slide set.
- Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C by Allison M. Bell, et al.
Summary: A review of the current literature about elbasvir/grazoprevir.
Doing the math on hepatitis C virus treatment by Shruti H. Mehta and David L. Thomas
Summary: A list of the benefits of hepatitis C treatment.
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial by Zobair M. Younoss, et al. (Published online: March 5 2016)
Summary: Hep C symptoms and treatment side effects can affect quality of life. This study looked at quality of life during and after treatment with sofosbuvir/velpatasvir. The trial concluded that quality of life was better during and after treatment with sofosbuvir/velpatasvir when compared with a treatment placebo.
Conclusion: Curing hepatitis C decreases portal pressure, which drives liver-related complications. However, the more damage patients have, the less it heals.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial by Imam Waked, et al. (AbbVie funded study)
Summary: Treated 160 patients with hep C genotype 4, with or without liver cirrhosis, for 12 or 24 weeks. Headaches and fatigue were the most common side effects. The study found that the treatment was well tolerated and that longer treatment times didn’t improve cure rate.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial by Tarik Asselah, et al. (AbbVie funded study)
Summary: The study looked at the treatment Technivie (ombitasvir/ paritaprevir/ ritonavir) and ribavirin taken for 12 and 16 weeks by patients with hep C genotype 4 and liver cirrhosis. The extended treatment between 12 and 16 weeks didn’t seem to benefit patients.